Colorectal cancer (CRC) originates in either the colon or the rectum. It is one of the most common types of cancers, and is the third most common cancer among men and the second most common in women (ACS, 2017a; Ferlay et al., 2016). CRC is a high-mortality cancer, with mortality rates just behind those of lung, liver, and stomach cancer. It’s global age-standardized mortality rates are 20.6 and 14.3 deaths per 100,000 population for men and women, respectively (Ferlay et al., 2016). Most cases of CRC present as adenocarcinomas, but other types of CRC include gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, primary colorectal lymphoma, leiomyosarcoma, melanoma and squamous cell carcinoma (Kim et al., 2016).

China has the most newly diagnosed CRC cases in Asia-Pacific (APAC). In 2011, there were 310,200 incident cases in the country and this rose to 376,300 in 2015. CRC is the most common malignancy among Chinese males, with an estimated incidence of 215,700 men and 160,600 women in 2015. Mortality in 2011 stood at 149,700, and in 2015 rose to 191,000 (Chen et al., 2016).

In Japan, the incidence and mortality of CRC have substantially increased. In 2012, the incidence of colon and rectum cancer in Japan was 87,800 and 46,800 cases respectively, and mortality was 32,200 and 15,100 cases (NCC, 2016a). CRC is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms among women, and the third largest among men (Watanabe et al., 2015). In 2016, there were an estimated 147,200 new CRC cases and 51,600 deaths in the country (NCC, 2016b).

In Australia, the five-year survival rate increased from 50% between 1984 and 1988 to 69% between 2009 and 2013. Improvement in survival from CRC may be due to earlier diagnosis and the availability of better treatment options (AGCA, 2017). The incidence of CRC is still several folds lower in India than in most developing and developed countries (Mallath, 2014). However, the country has witnessed a steady increase in numbers in line with its increasing urbanization.

The report “Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market” analyzes the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. Furthermore, this report helps to understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.

The CRC Asia-Pacific market will be valued at $7.9 billion in 2023, growing from $4.7 billion in 2016 at a CAGR of 7.9%.

How will immune checkpoint inhibitors such as Keytruda and Tecentriq contribute to growth?

What effect will patent expirations of currently branded therapies have on market value?

The CRC pipeline is large and diverse, with an strong presence of mAbs and targeted therapies

What are the common targets and mechanisms of action of pipeline therapies?

Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients?

What implications will the increased focus on targeted therapies have on the future of CRC treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

How have the late-stage therapies performed in clinical trials?

How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.

How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?

How could changes in risk factors such as population age, obesity and lifestyle influence the market?

Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $3 billion.

How do deal frequency and value compare between target families and molecule types?

What were the terms and conditions of key licensing deals?

Reasons to buy

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.

Visualize the composition of the CRC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.

Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.

Predict CRC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.

Identify commercial opportunities in the CRC deals landscape by analyzing trends in licensing and co-development deals.